Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hexokinase 2 | 0.1671 | 1 | 0.5 |
Onchocerca volvulus | 0.1671 | 1 | 1 | |
Loa Loa (eye worm) | hexokinase type II | 0.1671 | 1 | 1 |
Leishmania major | hexokinase, putative | 0.1671 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.1671 | 1 | 0.5 |
Toxoplasma gondii | hexokinase | 0.1671 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.1671 | 1 | 0.5 |
Plasmodium falciparum | hexokinase | 0.1671 | 1 | 0.5 |
Onchocerca volvulus | 0.1671 | 1 | 1 | |
Entamoeba histolytica | hexokinase 1 | 0.1671 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.1671 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.1671 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.1139 | 0.1468 | 0.1468 |
Echinococcus multilocularis | hexokinase | 0.1671 | 1 | 0.5 |
Treponema pallidum | hexokinase (hxk) | 0.1671 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.1671 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.1671 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.1671 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.1671 | 1 | 0.5 |
Onchocerca volvulus | 0.1671 | 1 | 1 | |
Echinococcus granulosus | hexokinase type 2 | 0.1671 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.1671 | 1 | 1 |
Trypanosoma brucei | hexokinase | 0.1671 | 1 | 0.5 |
Schistosoma mansoni | hexokinase | 0.1671 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.1671 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.1671 | 1 | 0.5 |
Plasmodium vivax | hexokinase, putative | 0.1671 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.1671 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.1671 | 1 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.1671 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.